Advertisement

Topics

HiFiBiO Therapeutics Company Profile

08:06 EDT 23rd July 2018 | BioPortfolio


News Articles [777 Associated News Articles listed on BioPortfolio]

HiFiBiO Therapeutics raises $37.5m in Series B funding

HiFiBiO Therapeutics has secured $37.5m Series B financing to accelerate pipeline of antibody drugs to treat cancer and autoimmune disorders.

Boston's HiFiBiO Raises $37.5 Million from China Investors

HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, closed a $37.5 million Series B financing led by two China investors, Sequoia Capital and Lyfe Capital. According to Hi...

Funding round brings in $37.5M for HiFiBio

A round of Series B funding brought in $37.5 million for cancer and autoimmune company HiFiBiO Therapeutics.  -More- 

HiFiBio raises $37.5mm in Series B round

Therapeutic antibody developer HiFiBio Therapeutics raised $37.5mm through an oversubscribed Series B round led by Sequoia China and LYFE Capital. New investors Legend Star Capital and Proxima Venture...

HiFiBio raises $37.5M series B

HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders

Multinational biotherapeutics company announces a new leadership team, expands its global footprint and advances an innovative portfolio of immune modulators for unmet medical nee...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

PubMed Articles [446 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [146 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1245 Associated Companies listed on BioPortfolio]

HiFiBiO SAS

HiFiBiO SAS is advancing an innovative and integrated discovery engine that creates unparalleled opportunities for discovering novel, differentiated therapeutic antibodies against...

HiFiBiO Therapeutics

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "HiFiBiO Therapeutics" on BioPortfolio

We have published hundreds of HiFiBiO Therapeutics news stories on BioPortfolio along with dozens of HiFiBiO Therapeutics Clinical Trials and PubMed Articles about HiFiBiO Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HiFiBiO Therapeutics Companies in our database. You can also find out about relevant HiFiBiO Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record